Showing 1141-1150 of 18563 results for "".
Radiation Therapy & Prostate Imaging
https://reachmd.com/programs/clinicians-roundtable/radiation-therapy-prostate-imaging/3166/Keeping closer tabs on the intrafractional movement of the prostate during radiation therapy will continue to play an increasingly significant role in improving our overall success when treating prostate cancer. So says Dr. Charles Enke, professor and chair of radiation oncology at the University ofInformation Technology in Medicine
https://reachmd.com/programs/clinicians-roundtable/information-technology-in-medicine/914/In this segment, Dr. Wachter talks about the specific information technology advances that have most improved patient management thus far. He then previews future information technology support that will make a more important impact.Improving adherence to medical therapy
https://reachmd.com/programs/clinicians-roundtable/improving-adherence-to-medical-therapy/895/Dr. Michael Murray, Professor and Chair of Pharmacuetical Outcomes and Policy at North Carolina, will describe a recent study that showed increased medication compliance with simple pharmacy intervnetions.Development and Ethics of Lethal Injection
https://reachmd.com/programs/clinicians-roundtable/development-and-ethics-of-lethal-injection/541/Dr. Teresa Zimmers, Assistant Professor-Department of Surgery and Department of Cell Biology and Anatomy, University of Miami, Miller School of Medicine talks about the current protocol for lethal injection and how it came to be.Reducing Proteinuria and Function Loss in IgAN: A Recap of the NefigArd Trial
https://reachmd.com/programs/frontlines-iga-nephropathy/reducing-proteinuria-and-function-loss-in-igan-a-recap-of-the-nefigard-trial/26940/Dive into a study focused on how the treatment option Nefecon may be able to reduce proteinuria and protect kidney function in IgAN patients.ctDNA-Guided Immunotherapy Shows Survival Benefit in MIBC: IMvigor011 Results
https://reachmd.com/programs/project-oncology/ctdna-immunotherapy-survival-mibc-imvigor011/36307/Presented at the 2025 ESMO Congress, the IMvigor011 phase 3 trial evaluated a ctDNA-guided strategy for administering adjuvant atezolizumab in patients with muscle-invasive bladder cancer (MIBC) following radical cystectomy. Patients with high-risk pathological features were monitored using a personUnderstanding the Caregiver Burden in TK2 Deficiency: New Insights from a Study
https://reachmd.com/programs/clinicians-roundtable/understanding-the-caregiver-burden-in-tk2-deficiency-new-insights-from-a-study/37636/Caring for individuals with thymidine kinase 2 (TK2) deficiency can place extraordinary demands on families, yet caregiver experiences are often overlooked in clinical care. To shed light on this burden, a mixed-methods study explored the physical, emotional, and financial impacts on caregivers. HerExamining Schizophrenia Risk: The Influence of B12 Levels in Early Pregnancy
https://reachmd.com/programs/neurofrontiers/examining-schizophrenia-risk-the-influence-of-b12-levels-in-early-pregnancy/32310/A recent study investigated how maternal B12 levels in early pregnancy might impact schizophrenia risk in offspring. Here’s what it found.Impacts on Access to Eye Care: Key Socioeconomic Factors
https://reachmd.com/programs/clinicians-roundtable/impacts-on-access-to-eye-care-key-socioeconomic-factors/14631/Have recent findings helped clinicians better identify socioeconomic factors among patients with glaucoma? Find out.Navigating Diagnostic Challenges in Food Protein-Induced Enterocolitis Syndrome
https://reachmd.com/programs/frontlines-food-allergies/navigating-diagnostic-challenges-in-food-protein-induced-enterocolitis-syndrome/30041/Food protein-induced enterocolitis syndrome (FPIES) is a rare, non-IgE-mediated food allergy in infants and young children that causes delayed, severe gastrointestinal symptoms without typical allergic signs. Learn about the challenges associated with diagnosing FPIES with Dr. Anna Nowak-Wegryzn, Pr